Search

Your search keyword '"Aulagner G"' showing total 35 results
Start Over Author "Aulagner G" Database Supplemental Index
35 results on '"Aulagner G"'

1. Cost-effectiveness of stent-retriever thrombectomy in large vessel occlusion strokes of the anterior circulation: Analysis from the French societal perspective

Author

Barral, M., Armoiry, X., Boudour, S., Aulagner, G., Schott, A.-M., Turjman, F., Gory, B., and Viprey, M.

Abstract

To determine the cost-effectiveness of stent retriever thrombectomy (SRT) added to standard of care (SOC) in large vessel occlusion (LVO) strokes, adopting the French societal perspective given the lack of published studies with such perspective.

Published
2020
Full Text
View/download PDF

3. Xenograft biologic mesh in parietal and general surgery: Technical assessment and review of clinical effectiveness and safety data.

Author

Sainfort, A., Denis Hallouard, I., Hartmann, D., Aulagner, G., Francois, Y., Tiffet, O., Barabino, G., Nuiry, O., and Armoiry, X.

Abstract

Summary Study aim To describe the main technical characteristics of biologic prostheses used for parietal reinforcement and to present the state of the art on their risk/benefit ratio. Methods We conducted a technical analysis of manufacturer specifications of the biologic prostheses that are currently available in France accompanied by a literature review by selecting meta-analyses and systematic reviews, randomized controlled trials and publications of health technology rating agencies. Results Biological implants for parietal reinforcement are mainly intended for use in a contaminated environment where the use of synthetic prostheses is contra-indicated. We identified fourteen systematic reviews and meta-analyses and one randomized controlled trial. Six ongoing clinical trials were identified as well as two clinical trials that had been interrupted. In the current state of knowledge, there are no high-level evidence data on the therapeutic contribution of biologic prostheses that allow prioritization of the various biologic prostheses according to their characteristics or their different manufacturing processes. Conclusion Pending the results of current randomized controlled trials to validate the indications and an eventual specific reimbursement, indications for the use of biologic parietal reinforcement prostheses seems to be limited to rare clinical situations and only after collegial discussion. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

4. Stent retriever thrombectomy for acute ischemic stroke: A systematic review and meta-analysis of randomized controlled trials, including THRACE

Author

Barral, M., Boudour, S., Viprey, M., Giroudon, C., Aulagner, G., Schott, A.-M., Turjman, F., Armoiry, X., and Gory, B.

Abstract

Endovascular thrombectomy has become the reference therapy for patients with large vessel occlusion (LVO). However, no meta-analysis including the THRACE Trial has yet been reported. Thus, the present review assessed the outcomes of stent retriever thrombectomy added to medical care compared with medical care alone in LVO patients.

Published
2018
Full Text
View/download PDF

5. Impact économique à l’hôpital de dispositifs médicaux non remboursés en sus des GHS : exemple des prothèses de renfort biologiques

Author

Sainfort, A., Denis-Hallouard, I., Aulagner, G., Nuiry, O., and Armoiry, X.

Abstract

Présenter une méthodologie d’évaluation de l’impact économique des dispositifs médicaux (DM) non remboursés en sus des groupes homogènes de séjours (GHS) à travers l’exemple des prothèses biologiques de renfort pariétal.

Published
2017
Full Text
View/download PDF

6. Current trends in vasopressor use to the operating room: A pharmacoepidemiologic study in French teaching and military hospitals

Author

Bauducel, M., Piriou, V., Dussart, C., Aulagner, G., and Armoiry, X.

Abstract

Phenylephrine, ephedrine and norepinephrine are the vasopressors most commonly used in the operating room to treat anaesthesia-induced hypotension. Two new diluted forms of phenylephrine were released in 2011 (500μg/10mL and 500μg/5mL). We initiated a study to evaluate trends in the use of vasopressors in the operating room in French hospitals over the period 2011–2014.

Published
2017
Full Text
View/download PDF

7. Implants biologiques de renfort pariétal en chirurgie viscérale et digestive : évaluation technique et revue des données d’efficacité clinique et de tolérance

Author

Sainfort, A., Denis Hallouard, I., Hartmann, D., Aulagner, G., Francois, Y., Tiffet, O., Barabino, G., Nuiry, O., and Armoiry, X.

Abstract

Décrire les principales caractéristiques techniques des prothèses biologiques de renfort pariétal et présenter l’état de l’art sur leur rapport efficacité/tolérance.

Published
2016
Full Text
View/download PDF

8. Évaluation de la sécurisation de la dispensation médicamenteuse dans trois centres hospitaliers universitaires d’Abidjan (Côte d’Ivoire)

Author

Abrogoua, D.P., Sangaré, A.Y., Doffou, E., and Aulagner, G.

Abstract

La sécurisation du circuit du médicament participe à l’amélioration de la qualité des soins. L’objectif de notre étude était d’évaluer le niveau de sécurité actuel de la dispensation hospitalière à Abidjan (Côte d’Ivoire).

Published
2016
Full Text
View/download PDF

9. Coûts directs de prise en charge des scolioses infantiles et juvéniles sévères : estimations en fonction de l’utilisation des tiges de croissance conventionnelles ou des tiges de croissance magnétiques

Author

Charroin, C., Abelin-Genevois, K., Cunin, V., Berthiller, J., Constant, H., Kohler, R., Aulagner, G., Serrier, H., and Armoiry, X.

Abstract

L’inconvénient majeur de la prise en charge des scolioses graves de survenue précoce (SGP) par la technique sans fusion avec distraction chirurgicale (tige de croissance conventionnelle) est la nécessité de recourir à des chirurgies itératives pendant l’enfance. La diffusion récente des tiges de croissance magnétiques (TCM) offre la possibilité d’éviter de telles chirurgies et par conséquent, d’améliorer la qualité de vie des patients.

Published
2014
Full Text
View/download PDF

11. Influence of Underlying Disease on Busulfan Disposition in Pediatric Bone Marrow Transplant Recipients A Nonparametric Population Pharmacokinetic Study

Author

Bertholle-Bonnet, V, Bleyzac, N, Galambrun, C, Mialou, V, Bertrand, Y, Souillet, G, and Aulagner, G

Abstract

Busulfan is an alkylating agent used in a conditioning regimen prior to bone marrow transplantation. Busulfan has a narrow therapeutic index, giving rise to major liver toxicity (veno-occlusive disease), and a wide interpatient and intrapatient pharmacokinetic variability. This report presents the results of a population pharmacokinetic analysis leading to models based on underlying diseases requiring bone marrow transplantation. One hundred children received oral busulfan-based conditioning regimens between March 1998 and February 2006. Busulfan pharmacokinetic parameter estimates (Ka, first order absorption rate constant; Vs, volume of distribution related to the body weight; and Cl/F, apparent clearance) were estimated by using the nonparametric adaptative grid (NPAG) algorithm in patients divided into four groups according to initial diagnosis: metabolic diseases, hemoglobinopathies, hematological malignancies, and immune deficiencies. Ka and Vs did no differ significantly in the four subgroups. Cl/F and areas under the plasma concentration curve were significantly different in the four groups. Cl/F was significantly higher in the hemoglobinopathies group (P= 0.002), with a mean value of 7.78 L · h−1, whereas the immune deficiencies group was characterized by the lowest Cl/F (3.59 L · h−1). Interindividual variability was shown by high interindividual parameter percent coefficients of variation (CV%) but, nevertheless, with less diversity in the population parameter distributions for Vs in the three subgroups-metabolic diseases, hemoglobinopathies, and malignant diseases-and in Cl/F for patients with hemoglobinopathies. The fit was good for busulfan concentration predictions based on Bayesian individual posterior values, with little bias and good precision. In comparison with the overall population, the only model of subgroup presenting a greater precision was patients with hemoglobinopathies (P= 0.002). Use of these more specific models of a given disease may well result in more accurate individualization of busulfan dose regimens, especially in very sparse blood sampling situations.

Published
2007
Full Text
View/download PDF

13. Influence des manipulations des tubulures de perfusion reliées à un cathéter central sur les infections à staphylocoques coagulase négative chez les prématurés

Author

Constant, H., Crassard, G., Girelli, M., Putet, G., and Aulagner, G.

Abstract

Objectifs—Le but de ce travail était de déterminer les types de manipulations de tubulures et de cathéters susceptibles d’entraîner des infections à staphylocoques coagulase négative chez les prématurés porteurs de cathéters centraux.

Published
1999
Full Text
View/download PDF

14. Abstracts of papers Rational use of drugs

Author

Dukes, M., Elenbaas, Robert, Tognoni, G., Smith, Dorothy, Lunde, Inga, Leufkens, H., Hekster, Y., Bakker, A., Ostino, G., Petri, H., Sturmans, F., Banta, H., Rutten, F., Martens, L., Noyce, P., Merkus, F., Jong-v.d.Berg, Lolkje, Haaijer-Ruskamp, Flora, Dukes, Graham, Vidgren, B., Vidgren, S., Martini, N., Sala, M., Scroccaro, G., Olivencia, P., McLcod, D., Coln, W., Hartzcma, A., Thaver, C., Rodriguez-Sasiain, J., Sangroniz, B., Mauleon, M., Wood, M., Martinez, M., Leinebø, O., Saugen, J., Marini, P., Olivato, R., Alberola, C., Cruz-Martos, E., Cruz, T., Marfagon, N., Tejada, A., Denig, P., Haaijer-Ruskamp, F., Wesseling, H., Versluis, A., Gascón, M., Horne, Robert, Hough, Jane, Klazinga, N., Everdingen, J., Broek, P., Roberts, D., Veitch, G., Tan, K., Holland, D., Allwood, M., Nicholls, A., Astobieta, A., Calvo, R., Rodriquez-Sasiain, J., Barriquand, D., Pochon, C., Aulagner, G., Vial, A., Dumarest, C., Maire, P., Jelliffe, R., Brouwers, J., Cramer, K., Gulyas, J., Kam, H., Sijtsma, J., Donadio, C., Tramonti, G., Garcea, G., Costagli, M., Lucchetti, A., Giordani, R., Paizis, G., Pierotti, R., Falcone, G., Bianchi, C., Gallastegui, C., Farré, R., Jiménez, I., Mangues, M., Guasch, E., Ginovart, G., Sagrera, X., Raspall, F., Queralto, J., Kovarik, J., Rademaker, C., Verhoef, J., Silvestri, L., Caputo, M., Andrew, M., Toverud, E., Jimenez, I., Castro, I., Alvarez, E., Altimiras, J., Leur, J., Muller, N., Turnhout, J., Mendizabal, L., Sasiain, J., Morana, G., Ofstad, K., Timenes, A., Vroom, J., Berg, L., Berg, P., Gier, J., Ferres, J., Recoder, O., Sanchez, Rio, Garcia, M., Julia, A., Balet, A., Farre, R., Manques, M., Berod, T., Dufay, E., Naveau, C., Combe, M., Sauvageon, A., Hansen, Erik, Christensen, Jens, Lie-A-Huen, L., Kinqma, J., Meijer, D., Meur, F., Isoard, P., Salek, M., Finlay, A., Khan, G., Luscombe, D., Stuurman, A., Boidin, M., Wallenius, K., Ojala, R., Kariluoto, A., Ikonen, M., Paes, A., Blom, A., Bakker, A., Wallenius, S., Enlund, H., Vainio, K., Codina, C., Roca, M., Sardà, P., Corominas, N., Massó, J., Ribas, J., Kentra, K., Myllyntausta, M., Saarenpää, M., Airaksinen, M., Mendarte, L., Rimola, A., Meisters, R., Hekster, Y., Janssen, W., Cox, A., Kempen, R., Aerdts, S., Dalen, R., Clasener, H., Festen, J., Schjphorst, PP, Benraad, HB, Asten, P., Wit, R., Muller, N., Limbeek, R., Nagel, H., Mgyboom, R., Stricker, B., Berg, B., Nelen, T., Tijssen, T., Wassink, P., Wassink-L'Ortije, M., Gascón, P., Selva, C., Bassons, T., Pardo, C., Mas, M., Saqalés, M., Sánchez, F., Mercade, V., Pujol, R., Agustí, C., Cano, M., Gurrera, T., Gorchs, M., Fabregas, X., Murgui, L., Verdaguer, A., Witjes, W., Vollaard, E., Crul, B., Limpens, C., Ahonen, K., Klaukka, T., Vohlonen, I., Martikainen, J., Goldenberg, Daniel, Brodsky, Andres, Aparici, Ines, Argeri, Cecilia, Goldenberg, D., Saidman, C., Sevinski, L., Allevato, N., Mujico, B., Ubogui, J., Dorfman, P., Rodriguez, Lupo, Varela, M., Higa, J., Fourrier, Annie, Larrouturou, Philippe, Samarran, Claire, Huchet, Jacqueline, Barber, N., Party, N., Wilson, P., Eide, Grethe, Horvei, Kari, Kruse-Jensen, Angelika, Wold, Ingrid, Møark, Turid, Barrett, C., Tugwell, A., Søndergaard, B., Rasmussen, M., Davidsen, F., Hey, H., Kierkeby, L., Riis, L., Korhonen, M., Vidgren, P., Ojanen, T., Vidqren, M., Ferrés, J., Sanchez, T., Gallastequi, C., Julià, A., Herings, R., Stricker, B., Janssen, A., Dinter, Heike, Janssen, A., Barbaut, X., Proust, S., Amlagner, G., Eskens, F., Clasener, H., Vollaard, E., Arnoldussen, E., Sieradzki, E., Wanat-Słupska, E., Zlółkowska, M., Pankowska, I., Mazur, R., Ksiazkiewicz, B., Jankowski, A., Marzec, A., Marzec, C., Marzec, M., Marzec, J., Marzec, A., Mungall, D., Portnoy, Lynne, Lucas, F., Kadir, F., Pijpers, A., Vulto, A., Zuidema, J., Tan, K., Sutton, P., Samu, Antal, Murphy, John, Chapman, Ronnie, Wieringa, Nicolien, Gier, J., Rolloos, J., Voesten, M., Meijer, P., Koning, G., Salek, S., Reerink, E., Mungall, D., Farrow, L., Raskob, G., Rosenbloom, D., Hull, R., Ferres, J., Torras, A., Farre, R., Recorder, O., Garcia, M., Torras, C., Cubellsl, J., Font, M., Madridejos, R., Catalán, A., Huguet, M., Franquesa, N., Gratacós, J., Martinez, M., Saltó, A., Kleijn, E., Wee, R., Holmberg, N., and Brenninkmeijer, R.

Published
1989
Full Text
View/download PDF

15. Determination of Six Thioguanine Nucleotides in Human Red Blood Cells Using Solid-Phase Extraction Prior to High Performance Liquid Chromatography

Author

Bonnefous, J. L., Gendre, Ph., Guillaumont, M., Frederich, A., and Aulagner, G.

Abstract

A sensitive and rapid assay for the 6 thioguanine nucleotides (6TGN), major intracellular active metabolite of 6 Mercaptopurine, in human Red Biood Cells (RBCs) was developed. This assay is based on the hydrolysis of 6TGN to 6 Thioguanine (6TG) followed by a solid-phase extraction prior to HPLC analysis. A KROMASIL-C18 column was used to separate. Analytical recovery for 6TGN was 58 % (coefficient of variation 6 %). The limit of detection was 25 pmol per 8.108 RBCs The assay was linear within the range 25-1600 pmol per 8.10s RBCs. The advantage of this technique is that it does not require any toxic solvant. This assay may contribute to monitoring the patient's compliance in leukemic children undergoing 6 Mercaptopurine therapy.

Published
1992
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results